152552-64-2

Basic information

• Product Name: 4-(benzyloxy)-3-fluorobenzoic acid
• Synonyms: 4-(benzyloxy)-3-fluorobenzoic acid
• CAS NO: 152552-64-2
• Molecular Formula: C₁₄H₁₁FO₃
• Molecular Weight: 246.2337432
• Mol File: 152552-64-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(benzyloxy)-3-fluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-3-fluorobenzoic acid(152552-64-2)
• EPA Substance Registry System: 4-(benzyloxy)-3-fluorobenzoic acid(152552-64-2)

Safety Data

• Hazardous Substances Data: 152552-64-2(Hazardous Substances Data)

Upstream product

• 124-38-9 carbon dioxide 
• 133057-82-6 1-benzyloxy-4-bromo-2-fluorobenzene 
• 2105-94-4 4-bromo-2-fluorophenol 
• 100-39-0 benzyl bromide 
• 350-29-8 3-fluoro-4-hydroxybenzoic acid 
• 1379604-20-2 benzyl-4-(benzyloxy)-3-fluorobenzoate 

Downstream Products

• 179066-15-0 4-Benzyloxy-3-fluoro-benzoic acid (R)-1-ethyl-heptyl ester 
• 391217-82-6 4-Benzyloxy-3-fluoro-benzoic acid 3-[4-(4-cyano-phenoxycarbonyl)-phenoxycarbonyl]-phenyl ester 
• 146967-99-9 4-benzyloxy-3-fluoro-benzoyl chloride 
• 866603-17-0 (+)-7-(3-fluoro-4-benzyloxybenzoyloxy)-2-naphthyl (R)-2-[4-(3-fluoro-4-benzyloxybenzoyloxy)phenyloxy]propionate 
• 143725-37-5 3-Fluoro-4-hydroxy-benzoic acid (S)-1-methyl-heptyl ester 
• 356058-45-2 1-propylbutyl 3-fluoro-4-hydroxybenzoate 

Relevant articles and documents

BICYCLIC COMPOUND

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS

Compounds that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein- coupled receptor GPR119 in animals are described herein.

AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS

The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are each hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by cytokines.

The synthesis and mesomorphic properties of some novel antiferroelectric liquid crystals

Several esters have been synthesised that exhibit the antiferroelectric smectic C phase. The core structures, like virtually all antiferroelectric materials, are very similar to that of MHPOBC. Lateral fluoro substituents have been used to reduce melting points and to investigate their effect on mesomorphic properties, spontaneous polarisation and tilt angle. A new device format reported by Lagerwall requires antiferroelectric liquid crystals with a 45° tilt angle. Novel antiferroelectric materials were prepared with fluoro substituents in lateral positions and in a terminal chain to provide low melting points, high antiferroelectric phase stability, high spontaneous polarisation and tilt angles of up to 45°. The synthetic routes to the novel materials are discussed, and the transition temperatures, tilt angles and spontaneous polarisations are compared to those of known materials.

Electroclinic and antiferroelectric properties of (R)-(-)-nonan-3-yl 4-(4′-dodecyloxybiphenyl-4-ylcarbonyloxy)-3-fluorobenzoate

The synthesis of the novel chiral mesogen (R)-(-)-nonan-3-yl 4-(4′-dodecyloxybiphenyl-4-ylcarbonyloxy)-3-fluorobenzoate and a discussion of its various liquid-crystalline properties are reported. Initial optical microscopy studies revealed the presence of a smectic A* phase and what was at first thought to be a smectic C* phase; further examination of this compound as thin film preparations revealed the presence of s±1/2 disclinations suggesting that the phase is an antiferroelectric subphase. Furthermore, these observations were supported by results from both differential scanning calorimetry and contact miscibility studies using known smectic C*A standards. The antiferroelectric nature of the phase was confirmed by obtaining sharp threshold characteristic curves during electrical switching studies from the antiferroelectric to an induced ferroelectric phase. Additionally, the chirality of the compound results in a reduction in the environmental symmetry for the smectic A* phase, and this allows electroclinic switching in the pretransitional region of the smectic A* phase close to the smectic C*A transition to take place under suitable conditions.